First New Drug Approved for Idiopathic Nephrotic Syndrome in 70 Years

(MedPage Today) -- The FDA expanded the indications for the B-cell depleter obinutuzumab (Gazyva) to include idiopathic nephrotic syndrome, the agency announced on Friday, the first new option for the rare kidney disease in more than half a century...